Clinical trials: Major Depressive Disorder
Major Depressive Disorder
A Study of CX157 (TriRima) for the Treatment of Depression
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD).
- Trial name
- CX157-200 (NCT00739908)
- Testing
- CX157 (TriRima)
- Where
- 14 sites in United States
- Volunteers
- 285 people
- Sponsor
- CeNeRx BioPharma Inc.
Depression, Major Depressive Disorder
Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms
Ketamine has been shown to have an antidepressant effect when given intravenously in doses of 2mg/kg. Ketamine is used as a standard induction drug during general anesthesia.
- Trial name
- NCT02422303
- Testing
- ketamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Major Depressive Disorder
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00839423
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine XL
- Volunteers
- 426 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor…
- Trial name
- NCT00882362
- Testing
- OPC-14597 (Aripiprazole)
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Ketamine in the Treatment of Depression
Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug.
- Trial name
- NCT01558063
- Testing
- Ketamine, Saline, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Columbia University
Depression, Depressive Disorder
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
- Trial name
- NCT02452892
- Testing
- LFMS
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Tal Medical, Inc.
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Pilot Study of Duloxetine in Psychological Resilience
The purpose of this study is to explore benefits of duloxetine in enhancing psychological resilience and to understand the relevance of inhibiting of both serotonin (5HT) and norepinephrine (NE)to therapeutic responses.
- Trial name
- NCT00331799
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Irritable Bowel Syndrome
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder
The purpose of this study is to determine the safety and effectiveness of a nutritional supplement, the probiotic bacteria GanedenBC30.
- Trial name
- NCT01337609
- Testing
- Ganeden BC30
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Depression, Postpartum, Depression, Unipolar
Tracking Depression Symptoms With a Health Chatbot
The goal of this research is to bridge a significant "effectiveness" gap in the treatment of depression. The investigators have developed a chatbot which will assist in performing measurement-based care (MBC) via Facebook…
- Trial name
- NCT03990389
- Testing
- Chatbot Intervention
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Major Depressive Disorder
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
The current use of telepsychiatry, or psychiatric care using videoconferencing, is very limited. The present study investigates the use of this method with a depressed Chinese American population in a nursing home.
- Trial name
- NCT00505518
- Testing
- Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Disorder, Major
Switching to Duloxetine in Patients With Depression
The purpose of this study is to help answer the following research question: Whether switching to duloxetine improves depressed mood when current treatment did not work well for patients with depression.
- Trial name
- ARDENT (NCT00696774)
- Testing
- Duloxetine
- Where
- 2 sites in South Korea
- Volunteers
- 242 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Alcohol Abuse
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will…
- Conditions
- Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
- Trial name
- NCT00452543
- Testing
- acamprosate, escitalopram, Medical management
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission
KAP for Depression in Abstinent Opioid Users
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused…
- Conditions
- Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
- Trial name
- KReDO (NCT05193318)
- Testing
- Ketamine-assisted psychotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder…
- Trial name
- NCT00985725
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 33 sites in United States
- Volunteers
- 143 people
- Sponsor
- Shire
Depression
Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse
This study will compare the effectiveness of fluoxetine alone with the effectiveness of fluoxetine with cognitive behavioral therapy in increasing recovery and preventing relapse in youth with major depressive disorder.
- Trial name
- NCT00612313
- Testing
- Fluoxetine, Relapse prevention cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Texas Southwestern Medical Center